TYTarkan Yetisyigit

Tarkan Yetisyigit

*This is an algorithmically generated author record based on publicly available information.

Tarkan Yetisyigit has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global disparities in the availability and reimbursement of systemic therapies for renal cell carcinoma: results of the International ARON-AID Survey

    by Yuksel Urun, Kannan Sridharan, Anca Zgura, Anas Zayed, Martin Ignacio Zapata Laguado, Tarkan Yetisyigit, Akihiro Yano, Mike Wenzel, Nuno Vau, Deniz Tural, et al.

    Background: Renal Cell Carcinoma (RCC) represents a growing global health burden, with rising incidence and mortality worldwide. Despite major therapeutic advances, access to novel systemic treatments remains uneven across countries and regions. Methods: We conducted a cross-sectional, web-based international survey to assess the availability and reimbursement status of 20 innovative systemic therapies for RCC. Responses were collected from 144 clinicians, including medical oncologists, radiation oncologists, urologists, and nuclear medicine specialists, across 58 countries. Analyses examined associations between national income level, gross domestic product (GDP), and treatment availability. Findings: Thirty-six percent of the countries analyzed had at least 15 of the 20 therapies available. Full reimbursement for at least 15 of the selected innovative therapies was reported in six countries (10%), while 21 countries (36%) fully reimbursed 10-14 therapies and 13 countries (23%) reimbursed 1-9 therapies. In contrast, no full reimbursement for any of the assessed therapies was reported in 18 countries (31%). Higher national income level was significantly associated with greater availability of innovative therapies (Kruskal–Wallis test, P < .0001). Armenia (0.709), Greece (0.685), and Israel (0.666) exhibited the highest GDP-adjusted Drug Availability Index (DAI), whereas India (5.195), Nigeria (4.612), and Morocco (3.794) demonstrated the greatest number of available therapies per US$1000 of GDP per capita. Interpretation: Access to innovative systemic therapies for RCC remains highly unequal at the global level, with reimbursement posing a major barrier even where drugs are available. Internationally coordinated efforts addressing health policy, infrastructure, and equitable pricing are urgently required to ensure that advances in RCC treatment translate into improved outcomes for patients across diverse economic settings.

  • Clinical Implications and Prevalence of Duffy-Null Associated Neutrophil Count in Patients With Breast Cancer of Middle Eastern Ethnicity

    by Shruti Prem Sudha, Nabil M. Abdelfattah, Tarkan Yetisyigit, Taif Najeebi, Fatema Sajjad, Alia Abdullatif, Sara Alhajeri, Atef Shehata, Fatima Al-Ali, Shahad Al-Omari, et al.

    PURPOSE: Duffy-null associated neutrophil count (DANC), formerly known as benign ethnic neutropenia, is seen in people of African and Middle Eastern descent and does not represent a true neutropenic state. Individuals with DANC can be identified by the Duffy-null phenotype on red cells. There is evidence that cancer patients with DANC are not at an increased risk of infection with chemotherapy. The aims of this study were to assess the prevalence of DANC among patients with breast cancer of Middle Eastern ethnicity and to study treatment delays, infectious complications, and survival in these patients. METHODS: We retrospectively reviewed 493 patients with breast cancer treated in a referral oncology center in Bahrain. Patients with neutropenia or leukopenia at presentation with Duffy-null phenotype and no identifiable secondary causes of neutropenia were presumed to have DANC. Clinical details studied included treatment delays, filgrastim responsiveness, and episodes of febrile neutropenia. A contemporaneous group of patients with breast cancer without DANC were used for comparison. RESULTS: Seventy-two patients (14.6%) had a presumed diagnosis of DANC, and the median neutrophil count at presentation was 1.2 × 10 3 /µL (range, 0.4-2.1 × 10 3 /µL). Treatment delays and discontinuations were significantly more common in patients with DANC ( P < .001) and were not decreased by prophylactic filgrastim use. Patients with DANC were uniformly filgrastim responsive, and only one patient had neutropenic fever. There was no effect of treatment delay or DANC on OS or PFS. CONCLUSION: DANC is prevalent among patients with breast cancer in Bahrain, and Duffy phenotyping on red cells can be a surrogate marker for diagnosis. Treatment delays because of the apparent neutropenia are common in DANC; however, febrile neutropenia is uncommon. This study is of particular relevance in populations with a high prevalence of DANC.

  • Open Access

    The role of peripheral T lymphocyte subsets and PD-1 expression as a biomarker for neoadjuvant treatment response in breast cancer

    by Tarkan Yetişyiğit, Kubilay Karaboyun, Yakup İrIağaç, Eyyüp Çavdar, Meltem Öznur, Erdoğan Selçuk Şeber, Burhan Turgut

    Background: The prognostic and predictive role of the interaction of the immune system with the tumor during the disease process has become increasingly important in recent years. T lymphocyte subgroups in peripheral blood can be used to monitor this dynamic interaction. We evaluated the relationship between baseline peripheral T lymphocyte subsets and treatment response (best objective response) in 47 breast cancer patients receiving neoadjuvant chemotherapy. Methods: This study investigated the impact of initial peripheral T lymphocyte subsets on neoadjuvant chemotherapy response in patients with invasive ductal breast. A total of 47 consecutive patients whose peripheral blood samples were able was included in the study group. The patients’ T lymphocyte subsets were measured before treatment. The patients were then followed up to assess their treatment response. Results: In our study, we found a significant negative relationship between baseline CD3, CD4, and CD8 absolute counts and pathologic complete response. We also found that high CD4/programmed cell death protein 1 expression (OR: 0.212, 95% CI: 0.061–0.735, P = .015) and high CD8/programmed cell death protein 1 expression (OR: 0.250, 95% CI: 0.073–0.858, P = .028) from baseline peripheral T lymphocyte were correlated with poor pathologic complete response. Conclusions: These results suggest that T lymphocyte subsets may be a predictive biomarker for treatment response in patients with breast cancer undergoing neoadjuvant chemotherapy. Further studies are needed to confirm these findings and to identify the optimal T lymphocyte subset for predicting treatment response.


  • Real-Life Sensitivity and Specificity of a COVID-19 Ag Rapid Test Device in Haematology-Oncology Cases in a Tertiary-Care Educational University Hospital

    by Umran Elbahr, Nafisa Alwazzan, Clark Steven Delos Reyes, Jennie Pastrana, Chithra Vineeth, Suha Hejres, Tarkan Yeti̇şYi̇ğİt, Shruti Prem Sudha, Zainab Ibrahim, Elias Fadel, et al.

  • Associations of Nutritional Status, Oxidative Parameters, and Quality of Life of Breast Cancer Patients Before, During, and After Chemotherapy

    by Aysel Şahi̇n Kaya, Tarkan Yeti̇şYi̇ğİt, Ahsen Yilmaz, Savaş GÜZEL, Aslı AKYOL MUTLU

    Aim: We aimed to assess the associations between nutritional status, oxidative parameters, and quality of life before, during, and after chemotherapy (CT) in breast cancer patients. Material and Method: Clinical, anthropometric, demographic, quality of life, blood oxidative marker level, and dietary intake data of breast cancer patients who planned to CT were recorded. All collected data were compared between pre-CT, mid-CT, and post-CT time points. Results: Fifty women who were diagnosed with breast cancer and would start CT treatment were included in the study. Post-CT body weight and body mass index were significantly lower than the pre-CT values (p˂0.001). They both turned back to pre-CT levels at the end of CT with a decrease in total daily caloric and macronutrient intake. Consumption of specific food groups significantly decreased compared to their pre-CT consumption levels (p˂0.001). Blood oxidative stress marker analysis revealed a significant reduction in glutathione peroxidase levels with CT (p=0.007). Analysis of the quality-of-life scores revealed that post-CT scores were significantly higher than the pre-CT scores while the life quality was lowest in the mid-CT period. Conclusion: Adequate energy intake and antioxidant intake should be recommended to these patients during CT via dietary counseling to maintain healthy anthropometric measures, oxidative hemostasis, and quality of life.

  • Investigation of Serum Folate-Receptor-1 Levels in Patients with Non-Small Cell Lung Cancer

    by Aliye Çeli̇kkol, Erdoğan Selçuk ŞEBER, Savaş GÜZEL, Ahmet Yolcu, Tarkan Yeti̇şyi̇ği̇t, Ahsen Yi̇lmaz

    Objective: Histopathological overexpression of folate receptor-1 (FOLR1) involved in folate transport in cell growth has been reported in various cancers. Increased serum FOLR1(sFOLR1) has also been reported in epithelial ovarian cancer. The aim was to investigate sFOLR1 levels in non-small cell lung cancer (NSCLC) patients and the response prediction of the standard chemotherapy targeting folic acid metabolism. Method: In this prospective study, sFOLR1 levels were investigated in 30 healthy individuals and 60 patients with stage4 malign metastatic NSCLC before and after standard chemotherapy. The commercial immunoassay (ELISA) kit used for analysis of sFOLR1. Serum carcinoembryonic antigen (CEA), vitamin B12, and folate levels were also investigated. Result: In NSCLC patients sFOLR1 levels were significantly higher(p<0.001) than the healthy individuals. After 3 months of standard treatment, sFOLR1 was significantly lower in patients(p<0.001). Diagnostic accuracy was strong in the differentiation of NSCLC patients from healthy individuals (AUC= 0.966). with the cut-off point of 82.45 pg/ml, the sFOLR1 level was performed with 95% sensitivity and 99% specificity. Pretreatment sFOLR1 levels were significantly lower in patients with-response to standard chemotherapy(p<0.01). The best predictive value was determined as 393.80 pg/ml. At the end of the 401 days, a significant difference found in patients with high the sFOLR1 predictive value. The median overall survival (OS) duration was 288 days for all patients (95% GA 198.13-377.87). Median progression-free survival (PFS) was 321 days (95% GA 211.90-430.10). Conclusion: For monitoring standard chemotherapy with drugs targeting folic acid metabolism, sFOLR-1 levels may be important biomarker.